Bolt Biotherapeutics, Inc.
BOLT
Rank in Stocks
#28102
Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting... Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate cancerous cells. A key therapeutic in its pipeline is BDC-1001, an investigational treatment targeting the human epidermal growth factor receptor 2 (HER2). This compound is presently undergoing Phase I/II clinical evaluation for patients with HER2-positive solid tumors, including those exhibiting low HER2 expression. Beyond BDC-1001, the company is advancing several other programs: BDC-2034, which targets carcinoembryonic antigen for various indications such as colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody designed to reprogram crucial immune cells within the tumor microenvironment by interacting with macrophage cell-surface receptors. Bolt is also pursuing a programmed cell death-ligand 1 (PD-L1) initiative aimed at addressing tumors that prove resistant to existing immune checkpoint blockades. Incorporated in 2015 under its previous name, Bolt Therapeutics, Inc., before officially becoming Bolt Biotherapeutics, Inc. in July of the same year, the company maintains its corporate headquarters in Redwood City, California.
Share Price
$6.43
Last synced: 2026-11-09
Market Cap
$12.39M
Change (1 day)
-1.68%
Change (1 year)
33.68%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Bolt Biotherapeutics, Inc. (BOLT)
Category
Healthcare
Operating Margin for Bolt Biotherapeutics, Inc. (BOLT)
Operating Margin as of November 2026 TTM: -623.04%
According to Bolt Biotherapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is -623.04%. At the end of 2025 the company had an operating margin of -450.07%.
Operating Margin history for Bolt Biotherapeutics, Inc. from 2018 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -623.04% | 38.43% |
| 2025 | -450.07% | -52.62% |
| 2024 | -949.91% | -1.81% |
| 2023 | -967.45% | -38.64% |
| 2022 | -1,576.56% | -78.59% |
| 2021 | -7,364.13% | -65.41% |
| 2020 | -21,290.91% | 47.81% |
| 2019 | -14,404.19% | 0.00% |
| 2018 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.06% |
US
|
|
| -149.01% | -99.76% |
US
|
|
| 25.57% | -100.04% |
AU
|
|
| 31.23% | -100.05% |
BE
|
|
| 29.35% | -100.05% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Bolt Biotherapeutics, Inc.'s operating margin
What is Bolt Biotherapeutics, Inc.'s operating margin?
Bolt Biotherapeutics, Inc.'s operating margin is -623.04%, as of Nov 2026.
What was Bolt Biotherapeutics, Inc.'s operating margin in 2025?
In 2025, Bolt Biotherapeutics, Inc.'s operating margin was -450.07%, compared with -949.91% in 2024.
How has Bolt Biotherapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Bolt Biotherapeutics, Inc.'s operating margin was highest in 2025 (-450.07%) and lowest in 2020 (-21,290.91%).
How does Bolt Biotherapeutics, Inc.'s operating margin compare with similar companies?
Bolt Biotherapeutics, Inc.'s operating margin (-623.04%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.